US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds
Patent 11952349 was granted and assigned to Nuvation Bio on April, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 10 Apr, 2024
Golden AI
Edits made to:
Infobox (+33 properties)
Article (+331 characters)
US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds
Article
Patent abstract
The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Christopher Paul Miller0
Jayakanth Kankanala0
Jeremy Pettigrew0
Son Minh Pham0
Date of Patent
April 9, 2024
0Patent Application Number
170967430
Date Filed
November 12, 2020
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
